NFE2L2 and non-small cell lung carcinoma: This observation coupled with the prevalence of KEAP1/NRF2 pathway mutations in NSCLC lends support to further investigation of artesunate and an NRF2 inhibitor as a novel drug combination for the treatment for patients with NSCLC.